RxDoctor Payments Data

Barbara Schwartzberg

Denver, CONPI 1770547663

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $291,304 of the $292,083 with a category attached, or 99.7%. Elekta, Inc. accounts for 61.4% of it on its own, with 5 other manufacturers making up the rest.

$292,083in general payments, 2019–2025

Across 41 payments — averaging $7123.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Elekta, Inc.$179K
  • Novian Health Inc.$112K
  • Nucletron Operations B.v.$550
  • Stryker$149
  • Viiv Healthcare Company$58
  • Bayer$21
$253,332in research payments, 2019–2025

Across 28 payments — averaging $9047.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Icad, Inc$253K

What the payments were for

  • Consulting fees$291,304100%
  • Food & beverage$2290%
  • Education$5500%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Elekta, Inc.24$179,304
Novian Health Inc.10$112,000
Nucletron Operations B.v.1$550
Stryker2$149
Viiv Healthcare Company3$58
Bayer1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →